Consider Cardiovascular Disease When Recommending Metformin Add-Ons

Cardiovascular impact will be considered more when choosing meds to add to metformin...due to new evidence and updated Canadian guidelines.

We're used to suggesting diabetes meds based on their A1C lowering, side effects, cost, etc. But now CV impact will also be important.

Recent studies show a CV benefit for Jardiance (empagliflozin) and Victoza (liraglutide) in some type 2 diabetes patients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote